Word Health Organization Advises Against Remdesivir for COVID-19 Treatment

Word Health Organization Advises Against
Remdesivir for COVID-19 Treatment.
A World Health Organization (WHO) panel
announced on Friday that Gilead’s remdesivir
should not be used on COVID-19 patients. .
The panel cited a “lack of evidence” that remdesivir
improves survival or reduces the need for ventilation. .
Especially given the costs and resource
implications associated with remdesivir ...
the panel felt the responsibility should be on
demonstrating evidence of efficacy, which is
not established by the currently available data, WHO Panel, via Reuters.
Remdesivir, known also by the brand
name, Veklury, is one of two medicines
authorized to treat COVID-19 patients. .
But a trial led by the WHO last month showed that
the antiviral had little or no effect on COVID-19 patients
in regard to 28-day mortality or length of hospital stays. .
The ... panel found a lack of
evidence that remdesivir improved
outcomes that matter to patients, WHO Panel, via Reuters.
Gilead has since released a statement
in response, saying it's “disappointed”
in the new WHO guideline. .
The biotech company said "numerous credible national
organizations" had recognized remdesivir as a
"standard of care" for COVID-19 patients.
The WHO guidelines appear to ignore this
evidence at a time when cases are dramatically
increasing around the world and doctors
are relying on Veklury …, Gilead, via Reuters